Accéder au contenu
Merck

A Comprehensive Evaluation of the Activity and Selectivity Profile of Ligands for RGD-binding Integrins.

Scientific reports (2017-01-12)
Tobias G Kapp, Florian Rechenmacher, Stefanie Neubauer, Oleg V Maltsev, Elisabetta A Cavalcanti-Adam, Revital Zarka, Ute Reuning, Johannes Notni, Hans-Jürgen Wester, Carlos Mas-Moruno, Joachim Spatz, Benjamin Geiger, Horst Kessler
RÉSUMÉ

Integrins, a diverse class of heterodimeric cell surface receptors, are key regulators of cell structure and behaviour, affecting cell morphology, proliferation, survival and differentiation. Consequently, mutations in specific integrins, or their deregulated expression, are associated with a variety of diseases. In the last decades, many integrin-specific ligands have been developed and used for modulation of integrin function in medical as well as biophysical studies. The IC50-values reported for these ligands strongly vary and are measured using different cell-based and cell-free systems. A systematic comparison of these values is of high importance for selecting the optimal ligands for given applications. In this study, we evaluate a wide range of ligands for their binding affinity towards the RGD-binding integrins αvβ3, αvβ5, αvβ6, αvβ8, α5β1, αIIbβ3, using homogenous ELISA-like solid phase binding assay.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anti-Integrin αV Antibody, clone LM142, ascites fluid, clone LM142, Chemicon®